For CD8+ cell depletion experiments, the tumor-bearing mice were treated with CDDP (4 mg/kg, once at Day1) and anti–mouse CD8 mAb (twice a week from one day before the treatment initiation). This evidence concerns the gene CD8A and neoplasm.